OPKO Health, Inc. (OPK)
After hours:
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.2200 x 4200 |
| Ask | 1.2500 x 4200 |
| Day's range | 1.2000 - 1.2600 |
| 52-week range | 0.8500 - 2.2400 |
| Volume | |
| Avg. volume | 9,424,382 |
| Market cap | 857.3M |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
- GlobeNewswire
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with En
- GlobeNewswire
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency v
